Skip to content
May 5, 2026
Pharminent
Primary Menu
Home
Signal News
Biopharma Brief
Market Access Intelligence
Rare Disease Gene Therapy
Oncology
Week in Review
GLP-1 Competitive Market
NeuroMarket Pulse
Neurology Regulatory Interactive Calendar
Manufacturing Intelligence
Contact
Light/Dark Button
Search for:
Brief
Home
Signal News Directory
News
News
News
UCB Enters $2.2 Billion Deal to Acquire Candid Therapeutics
pharminent
May 4, 2026
You May Have Missed
News
UCB Enters $2.2 Billion Deal to Acquire Candid Therapeutics
pharminent
May 4, 2026
Commercial
Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq
pharminent
May 4, 2026
Other
223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease
pharminent
May 4, 2026
M&A / Deals
Eli Lilly to Acquire Kelonia Therapeutics
pharminent
May 4, 2026
